📊 BSX Key Takeaways
Is Boston Scientific Corp. (BSX) a Good Investment?
Boston Scientific demonstrates strong fundamental growth with 19.9% YoY revenue expansion and solid profitability margins (69% gross, 18% operating). The company maintains healthy financial leverage (0.46x debt/equity) and generates robust free cash flow of $3.7B, supporting operational efficiency and potential capital allocation.
Boston Scientific shows strong fundamental momentum, with nearly 20% revenue growth, high gross margins, and robust free cash flow generation that supports reinvestment and balance sheet flexibility. Financial health appears solid, with good liquidity, manageable leverage, and healthy interest coverage, although the sharp gap between revenue growth and net income growth suggests profit conversion should be monitored closely.
Why Buy Boston Scientific Corp. Stock? BSX Key Strengths
- Strong revenue growth of 19.9% YoY with gross margin expansion at 69%
- Solid free cash flow generation of $3.7B with 18.2% FCF margin demonstrates capital efficiency
- Conservative leverage with 0.46x debt/equity ratio and 10.4x interest coverage indicating financial stability
- Healthy liquidity position with 1.62x current ratio and $2.0B cash reserves
- Strong top-line growth with revenue up 19.9% year over year
- High profitability profile, including 69.0% gross margin and 18.2% free cash flow margin
- Solid balance sheet and debt service capacity, with 1.62x current ratio and 10.4x interest coverage
BSX Stock Risks: Boston Scientific Corp. Investment Risks
- Net income growth (0.2% YoY) significantly lags revenue growth, suggesting margin compression or operational challenges
- EPS growth of 55.2% appears driven by share buybacks rather than underlying earnings growth, masking operational weakness
- High insider activity (23 Form 4 filings in 90 days) may indicate elevated trading by company insiders
- Medical device sector faces regulatory headwinds and pricing pressures that could impact future margin sustainability
- Net income growth was only 0.2% despite strong revenue growth, indicating possible margin or expense pressure below the operating line
- Long-term debt of $11.14B is manageable but still meaningful relative to cash of $1.97B
- Sustaining near-20% revenue growth may become harder if operating leverage does not continue improving
Key Metrics to Watch
- Operating margin trends and cost structure management
- Free cash flow conversion and sustainability of $3.7B FCF generation
- Revenue growth momentum and organic versus acquisition-driven growth components
- Debt/equity ratio trajectory and capital allocation between debt reduction and reinvestment
- Net income and operating margin progression versus revenue growth
- Free cash flow generation and long-term debt reduction
Boston Scientific Corp. (BSX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Boston Scientific Corp. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BSX Profit Margin, ROE & Profitability Analysis
BSX vs Healthcare Sector: How Boston Scientific Corp. Compares
How Boston Scientific Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Boston Scientific Corp. Stock Overvalued? BSX Valuation Analysis 2026
Based on fundamental analysis, Boston Scientific Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Boston Scientific Corp. Balance Sheet: BSX Debt, Cash & Liquidity
BSX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Boston Scientific Corp.'s revenue has grown significantly by 69% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.07 reflects profitable operations.
BSX Revenue Growth, EPS Growth & YoY Performance
BSX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.2B | $468.0M | $0.32 |
| Q2 2025 | $4.1B | $322.0M | $0.22 |
| Q1 2025 | $3.9B | $493.0M | $0.33 |
| Q3 2024 | $3.5B | $468.0M | $0.32 |
| Q2 2024 | $3.6B | $270.0M | $0.18 |
| Q1 2024 | $3.4B | $314.0M | $0.21 |
| Q3 2023 | $3.2B | $188.0M | $0.12 |
| Q2 2023 | $3.2B | $260.0M | $0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Boston Scientific Corp. Dividends, Buybacks & Capital Allocation
BSX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Boston Scientific Corp. (CIK: 0000885725)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BSX
What is the AI rating for BSX?
Boston Scientific Corp. (BSX) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BSX's key strengths?
Claude: Strong revenue growth of 19.9% YoY with gross margin expansion at 69%. Solid free cash flow generation of $3.7B with 18.2% FCF margin demonstrates capital efficiency. ChatGPT: Strong top-line growth with revenue up 19.9% year over year. High profitability profile, including 69.0% gross margin and 18.2% free cash flow margin.
What are the risks of investing in BSX?
Claude: Net income growth (0.2% YoY) significantly lags revenue growth, suggesting margin compression or operational challenges. EPS growth of 55.2% appears driven by share buybacks rather than underlying earnings growth, masking operational weakness. ChatGPT: Net income growth was only 0.2% despite strong revenue growth, indicating possible margin or expense pressure below the operating line. Long-term debt of $11.14B is manageable but still meaningful relative to cash of $1.97B.
What is BSX's revenue and growth?
Boston Scientific Corp. reported revenue of $20.1B.
Does BSX pay dividends?
Boston Scientific Corp. does not currently pay dividends.
Where can I find BSX SEC filings?
Official SEC filings for Boston Scientific Corp. (CIK: 0000885725) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BSX's EPS?
Boston Scientific Corp. has a diluted EPS of $1.94.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BSX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Boston Scientific Corp. has a BUY rating with 80% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is BSX stock overvalued or undervalued?
Valuation metrics for BSX: ROE of 12.0% (sector avg: 15%), net margin of 14.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BSX stock in 2026?
Our dual AI analysis gives Boston Scientific Corp. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is BSX's free cash flow?
Boston Scientific Corp.'s operating cash flow is $4.5B, with capital expenditures of $876.0M. FCF margin is 18.2%.
How does BSX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 14.4% (avg: 12%), ROE 12.0% (avg: 15%), current ratio 1.62 (avg: 2).